Skip to main content

ADVERTISEMENT

Videos

Alexey Danilov, MD
Conference Coverage
10/21/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Alexey Danilov, MD, participated in a debate of optimal frontline therapies for patients with chronic lymphocytic leukemia in which he argued in favor of utilizing acalabrutinib.
At the 2024 Lymphoma, Leukemia &...
10/21/2024
Oncology
Benjamin Besse, MD, PhD
Conference Coverage
10/21/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD,...
10/21/2024
Oncology
Daniel Landsberg, MD
Conference Coverage
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia &...
10/19/2024
Lymphoma, Leukemia & Myeloma Network
Joshua Richter, MD
Conference Coverage
10/19/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joshua Richter, MD, discusses the role of measurable residual disease in the treatment of patients with multiple myeloma.
At the 2024 Lymphoma, Leukemia &...
10/19/2024
Lymphoma, Leukemia & Myeloma Network
Joanna Rhodes, MD
Conference Coverage
10/18/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Lymphoma, Leukemia & Myeloma Network
Gathering of Eagles Meeting August 23, 2024:
Videos
10/18/2024
Jon Krohmer on proposed CMS modifications to reimbursement for whole blood delivery; Jeffrey Goodloe on the fiscal impact of hospital bed delays on EMS systems; Aileen Marty on long COVID research; and more.
Jon Krohmer on proposed CMS modifications to reimbursement for whole blood delivery; Jeffrey Goodloe on the fiscal impact of hospital bed delays on EMS systems; Aileen Marty on long COVID research; and more.
Jon Krohmer on proposed CMS...
10/18/2024
EMSWorld
Aileen Marty presents the latest research on monkeypox; Crawford Mechem updates the group on the latest opioid challenges in Philadelphia; Paul Pepe presents on whole blood delivery in Texas; Gam Wijetunge discusses new initiatives at NHTSA; and more.
Videos
10/18/2024
Aileen Marty on monkeypox; Crawford Mechem on the latest opioid challenges in Philadelphia; Paul Pepe on whole blood delivery in Texas; Gam Wijetunge on what's new at NHTSA; and more.
Aileen Marty on monkeypox; Crawford Mechem on the latest opioid challenges in Philadelphia; Paul Pepe on whole blood delivery in Texas; Gam Wijetunge on what's new at NHTSA; and more.
Aileen Marty on monkeypox;...
10/18/2024
EMSWorld
Craig Sauter, MD
Conference Coverage
10/18/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Oncology
Beth Faiman, PhD, MSN
Videos
10/18/2024
Beth Faiman PhD, MSN, provides expert insight on tactics for managing oral toxicities associated with talquetamab treatment among patients with relapsed/refractory multiple myeloma.
Beth Faiman PhD, MSN, provides expert insight on tactics for managing oral toxicities associated with talquetamab treatment among patients with relapsed/refractory multiple myeloma.
Beth Faiman PhD, MSN, provides...
10/18/2024
APP Institute Oncology